Stocks · News reference
Artelo Biosciences announced that Professor Saoirse O'Sullivan will present data on its lead FABP5 inhibitor, ART26.12, at the IASP 2026 World Congress on Pain in Bangkok.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Artelo Biosciences announced it will present nonclinical data for ART27.13, a candidate for chemotherapy-induced neuropathic pain, at the IASP 2026 World Congress on Pain.
Filed: 2026-10-09 AccNo: 0001640334-26-001665 Size: 143 KB Item 8.01: Other Events
U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.